T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

October 31, 2007

Study Completion Date

June 30, 2012

Conditions
Head and Neck Cancer
Interventions
BIOLOGICAL

autologous EBV specific CTLs

"30-40cc of peripheral blood will be used to generate EBV specific CTLs~Group One:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 2 x 10\^7 cells/m2~Group Two:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 1 x 10\^8 cells/m2~Group Three:~Day 0 - 1 x 10\^8 cells/m2 Day 14 - 2 x 10\^8 cells/m2"

Trial Locations (2)

77030

Texas Children's Hospital, Houston

The Methodist Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00609219 - T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC | Biotech Hunter | Biotech Hunter